| 000 | 01716 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516141542.0 | ||
| 264 | 0 | _c20140109 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1468-1293 | ||
| 024 | 7 |
_a10.1111/hiv.12029 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJansen, A | |
| 245 | 0 | 0 |
_aPharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. _h[electronic resource] |
| 260 |
_bHIV medicine _cAug 2013 |
||
| 300 |
_a449-52 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 | _aAtazanavir Sulfate |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOligopeptides _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrrolidinones _xadministration & dosage |
| 650 | 0 | 4 | _aRaltegravir Potassium |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aColbers, E P H | |
| 700 | 1 | _avan der Ven, A J A M | |
| 700 | 1 | _aRichter, C | |
| 700 | 1 | _aRockstroh, J K | |
| 700 | 1 | _aWasmuth, J C | |
| 700 | 1 | _avan Luin, M | |
| 700 | 1 | _aBurger, D M | |
| 773 | 0 |
_tHIV medicine _gvol. 14 _gno. 7 _gp. 449-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/hiv.12029 _zAvailable from publisher's website |
| 999 |
_c22593145 _d22593145 |
||